VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum.
Lentiviral vectors transduce dividing and postmitotic cells and thus are being developed toward therapies for many diseases affecting diverse tissues. One essential requirement for efficacy will be that vector particles are resistant to inactivation by human serum complement. Most animal studies with lentiviral vectors have utilized VSV-G pseudotyped envelopes. Here we demonstrate that VSV-G pseudotyped HIV and FIV vectors produced in human cells are inactivated by human serum complement, suggesting that alternative envelopes may be required for therapeutic efficacy for many clinical applications of lentiviral vectors.
DePolo
N J
NJ
Chiron Corporation, Emeryville, California, 94608, USA.
Reed
J D
JD
Sheridan
P L
PL
Townsend
K
K
Sauter
S L
SL
Jolly
D J
DJ
Dubensky
T W
TW
D000818:Animals; D000998:Antiviral Agents; D001769:Blood; D002460:Cell Line; D006224:Cricetinae; D005822:Genetic Vectors; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics*
D000998:Antiviral Agents